Table 8 . Combination of immune checkpoint inhibitors and targeted therapies
IMMUNE CHECKPOINT INHIBITOR
TARGETED THERAPY |
CONDITION |
OTHER |
|
|
THERAPIES |
PHASE I |
NCT02013219 |
Atezolizumab / |
|
|
MPDL3280A |
NCT01998126
Ipilimumab / Yervoy or nivolumab / Opdivo
Erlotinib ( protein kinase inhibitor ) or alectinib ( anaplastic lymphoma kinase [ ALK ] inhibitor )
Erlotinib or crizotinib ( ALK inhibitor )
NCT01940809 |
Ipilimumab / Yervoy |
Dabrafenib ( BRAF inhibitor ), |
|
|
trametinib ( MEK inhibitor ), and / |
|
|
or nivolumab |
NCT02649686 Durvalumab / MEDI4736
Trastuzumab ( targets HER2 receptor )
Stage IIIB-IV , non-resectable EGFR-tyrosine kinase inhibitor ( TKI ) -treatment naive NSCLC or previously untreated EGFR mutation-positive advanced NSCLC ( erlotinib group ); treatment-naïve patients with anaplastic lymphoma kinase ( ALK ) -positive advanced NSCLC ( alectinib group )
Stage IV NSCLC or stage II-III NSCLC that could not be treated with standard treatment , with EGFR or ALK mutations
Metastatic or unresectable melanoma
Advanced / recurrent HER2 + breast cancer
NCT02572687 |
Ramucirumab ( targets VEGFR2 ) |
Gastric cancer , gastroesophageal junction adenocarcinoma , |
|
|
NSCLC , hepatocellular carcinoma |
NCT02133742 Pembrolizumab / MK-3475 / Keytruda
Axitinib ( small molecule tyrosine kinase inhibitor )
Advanced renal cell carcinoma
NCT02443324 |
Ramucirumab |
Metastatic or unresectable gastric adenocarcinoma , |
|
|
gastroesophageal junction adenocarcinoma ; NSCLC |
NCT02646748
INCB039110 ( JAKI selectivity ) or INCB050465 ( PI3K-delta inhibitor )
Advanced solid tumors , endometrial cancer , melanoma , microsatellite unstable ( MSI ) colorectal cancer , MMRdeficient tumors , NSCLC , renal cell carcinoma , head and neck squamous cell carcinoma , TNBC , transitional cell carcinoma of the genitourinary tract
NCT02357732 Nivolumab / Opdivo Dabrafenib and / or trametinib BRAF or NRAS-mutated metastatic melanoma
NCT02518958 RRx-001 ( epigenetic agent ) Malignant solid tumors , lymphoma
PHASE I / IB |
NCT01656642 |
Atezolizumab / |
|
|
MPDL-3280A |
Vemurafenib ( BRAF inhibitor ) and cobimetinib ( MEK inhibitor )
NCT01633970 Bevacizumab ( anti-VEGF ) or bevacizumab + various chemotherapy regimens
NCT02660034
BGB-A317 ( anti- PD-1 )
PHASE I / II |
NCT02657889 |
Pembrolizumab / |
|
|
MK-3475 / Keytruda |
NCT02130466
NCT02437136
BGB-290 ( PARP inhibitor )
Niraparib ( PARP inhibitor )
Dabrafenib ( BRAF inhibitor ) and trametinib ( MEK inhibitor )
Entinostat ( orally available histone deacetylase inhibitor )
Previously untreated BRAFV600-mutation positive metastatic melanoma
Advanced or metastatic solid tumors
Advanced solid tumors
TNBC , ovarian cancer , breast cancer , metastatic breast cancer , advanced breast cancer , stage IV breast cancer , fallopian tube cancer , peritoneal cancer
Melanoma
Advanced metastatic or recurrent NSCLC or melanoma
NCT02348008 |
Bevacizumab ( anti-VEGF ) |
Clear cell renal carcinoma after failure of at least one systemic therapy for metastatic disease ( including , but not limited to prior therapy with IL-2 , IFN , bevacizumab , VEGF TKI , or mTOR ) |
NCT02484404 Durvalumab / MEDI4736
NCT02027961
NCT02386111
Varlilumab ( anti- CD27 )
Olaparib ( PARP inhibitor ) or cediranib ( VEGFR inhibitor )
Dabrafenib ( BRAF inhibitor ) and trametinib ( MEK inhibitor )
Sunitinib ( VEGFR tyrosine kinase inhibitor )
PHASE II |
NCT01928576 |
Nivolumab / Opdivo |
Entinostat ( histone deacetylase |
|
|
|
inhibitor ) |
NCT02609984 Atezolizumab / MPDL3280A
CMB305 ( targets tumors expressing NY-ESO-1 )
Lung cancer , breast cancer , ovarian cancer , colorectal cancer , prostate cancer
Metastatic or unresectable melanoma
Renal cell carcinoma , urogenital cancer
Stage IIIB-IV NSCLC
Sarcomas
Chemotherapy
NCT02659384 |
Bevacizumab |
Platinum-resistant ovarian neoplasms |
… or acetyl |
|
|
|
salicylic acid |
NCT02332980 Pembrolizumab / MK-3475 / Keytruda
NCT02625337
NCT02336165 Durvalumab / MEDI4736
Ibrutinib ( BTK inhibitor ) and idelalisib ( P3K delta inhibitor )
Dabrafenib ( BRAF inhibitor ) and trametinib ( MEK inhibitor )
Bevacizumab ( anti-VEGF )
Relapsed or refractory chronic lymphocytic leukemia and other low grade B cell non-Hodgkin lymphoma
Metastatic melanoma
Glioblastoma
PHASE III NCT01668784 Nivolumab / Opdivo Everolimus ( mTOR inhibitor ) Advanced or metastatic clear-cell renal cell carcinoma
NCT02420821 Atezolizumab / MPDL3280A
Bevacizumab ( anti-VEGF )
PILOT |
NCT02210117 |
Nivolumab / Opdivo |
Bevacizumab ( anti-VEGF ) or |
|
|
|
ipilimumab |
Renal cell carcinoma
Metastatic renal cell carcinoma , eligible for cytoreductive nephrectomy , metastasectomy , or post-treatment biopsy